Derek P Narendra

List of Publications by Year in Descending Order

37 papers	18,325 citations	20 h-index	47 g-index
47 ext. papers	21,154 ext. citations	11.4 avg, IF	6.55 L-index

#	Paper	IF	Citations
37	Managing risky assets - mitophagy in vivo. *Journal of Cell Science*, **2021**, 134,	5.3	4
36	Mt-Keima detects PINK1-PRKN mitophagy with greater sensitivity than mito-QC. *Autophagy*, **2021**, 17, 3753-3762	10.2	8
35	Comment on "mt-Keima detects PINK1-PRKN mitophagy with greater sensitivity than mito-QC". *Autophagy*, **2021**, 1-2	10.2	2
34	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. *Annals of Neurology*, **2021**, 90, 35-42	9.4	6
33	α-Synuclein Deposition in Sympathetic Nerve Fibers in Genetic Forms of Parkinson's Disease. *Movement Disorders*, **2021**, 36, 2346-2357	7	3
32	Mitochondrial Dysfunction and Mitophagy in Parkinson's Disease: From Mechanism to Therapy. *Trends in Biochemical Sciences*, **2021**, 46, 329-343	10.3	67
31	Discovery of bactericides as an acute mitochondrial membrane damage inducer. *Molecular Biology of the Cell*, **2021**, 32, ar32	3.5	1
30	Finding genetically-supported drug targets for Parkinson's disease using Mendelian randomization of the druggable genome.. *Nature Communications*, **2021**, 12, 7342	17.4	2
29	Author response: Peripheral synucleinopathy in a DJ1 patient with Parkinson disease, cataracts, and hearing loss. *Neurology*, **2020**, 94, 944	6.5	
28	Detection of mitophagy in mammalian cells, mice, and yeast. *Methods in Cell Biology*, **2020**, 155, 557-579	1.8	3
27	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. *Movement Disorders*, **2020**, 35, 774-780	7	27
26	Loss of CHCHD2 and CHCHD10 activates OMA1 peptidase to disrupt mitochondrial cristae phenocopying patient mutations. *Human Molecular Genetics*, **2020**, 29, 1547-1567	5.6	15
25	Coupling APEX labeling to imaging mass spectrometry of single organelles reveals heterogeneity in lysosomal protein turnover. *Journal of Cell Biology*, **2020**, 219,	7.3	8
24	Metabolic Analysis at the Nanoscale with Multi-Isotope Imaging Mass Spectrometry (MIMS). *Current Protocols in Cell Biology*, **2020**, 88, e111	2.3	2
23	Peripheral synucleinopathy in a patient with Parkinson disease, cataracts, and hearing loss. *Neurology*, **2019**, 92, 1113-1115	6.5	12
22	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurology, The*, **2019**, 18, 1091-1102	24.1	562
21	CHCHD2 accumulates in distressed mitochondria and facilitates oligomerization of CHCHD10. *Human Molecular Genetics*, **2018**, 27, 3881-3900	5.6	22

20	Parkin and PINK1 mitigate STING-induced inflammation. *Nature*, **2018**, 561, 258-262	50.4	509
19	A Woman in Her 40s With Headache and New-Onset Seizures. *JAMA Neurology*, **2017**, 74, 476-480	17.2	
18	PARKIN/PINK1 Pathway for the Selective Isolation and Degradation of Impaired Mitochondria **2016**, 159-182		2
17	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838
16	An anomalous developmental venous anomaly. *Neurology*, **2014**, 83, 1033-4	6.5	2
15	Teaching NeuroImages: brain mass with hilar adenopathy: the importance of histologic diagnosis. *Neurology*, **2014**, 82, e161-2	6.5	2
14	PINK1 rendered temperature sensitive by disease-associated and engineered mutations. *Human Molecular Genetics*, **2013**, 22, 2572-89	5.6	20
13	PINK1 drives Parkin self-association and HECT-like E3 activity upstream of mitochondrial binding. *Journal of Cell Biology*, **2013**, 200, 163-72	7.3	186
12	Mitochondrial quality control mediated by PINK1 and Parkin: links to parkinsonism. *Cold Spring Harbor Perspectives in Biology*, **2012**, 4,	10.2	220
11	Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy*, **2012**, 8, 445-544	10.2	2783
10	Mechanisms of mitophagy. *Nature Reviews Molecular Cell Biology*, **2011**, 12, 9-14	48.7	2153
9	Targeting mitochondrial dysfunction: role for PINK1 and Parkin in mitochondrial quality control. *Antioxidants and Redox Signaling*, **2011**, 14, 1929-38	8.4	269
8	Parkin overexpression selects against a deleterious mtDNA mutation in heteroplasmic cybrid cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 11835-40	11.5	243
7	p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. *Autophagy*, **2010**, 6, 1090-106	10.2	580
6	Mitochondrial membrane potential regulates PINK1 import and proteolytic destabilization by PARL. *Journal of Cell Biology*, **2010**, 191, 933-42	7.3	859
5	Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. *Journal of Cell Biology*, **2010**, 191, 1367-80	7.3	989
4	PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. *PLoS Biology*, **2010**, 8, e1000298	9.8	1887
3	Parkin-induced mitophagy in the pathogenesis of Parkinson disease. *Autophagy*, **2009**, 5, 706-8	10.2	181

2	Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *Journal of Cell Biology*, **2008**, 183, 795-803	7.3	2766
1	When patients lack capacity: the roles that patients with terminal diagnoses would choose for their physicians and loved ones in making medical decisions. *Journal of Pain and Symptom Management*, **2005**, 30, 342-53	4.8	66